Adicet Bio, Inc., a clinical-stage biotechnology firm, reported a net loss of $116.8 million for the year ended December 31, 2025, compared to a net loss of $117.1 million for the previous year. Research and development expenses totaled $99.1 million, slightly down from $99.3 million in 2024, primarily due to decreased payroll and lab supply costs, offset by increased contracted research expenses. General and administrative expenses decreased by 19% to $23.0 million, mainly driven by lower stock-based compensation and reduced rent and office-related expenses.
The company's revenue stream remains non-existent, as it has no products approved for commercial sale. Interest income decreased significantly, falling 46% to $5.8 million, attributed to lower interest rates and reduced cash balances. Other expenses, net, increased by 98% to $0.4 million, primarily due to losses on the disposal of assets. As of December 31, 2025, Adicet Bio held $158.5 million in cash, cash equivalents, and short-term investments.
Operationally, Adicet Bio is focusing on advancing its pipeline of allogeneic gamma delta T cell therapies. Its lead product candidate, prula-cel, is currently in Phase 1 clinical trials for various autoimmune diseases, including lupus nephritis, systemic lupus erythematosus, and systemic sclerosis. The company expects to provide clinical updates on these trials in the first half of 2026. ADI-212, a next-generation candidate targeting prostate-specific membrane antigen, is slated for a regulatory filing in the third quarter of 2026, with patient enrollment expected to begin in the fourth quarter of the same year.
Adicet Bio discontinued the development of ADI-270 to prioritize resources on prula-cel and ADI-212. The company believes its current cash position will sustain operations into the second half of 2027. However, future success depends on clinical trial outcomes, regulatory approvals, and the ability to secure additional funding, which may be affected by unstable market conditions. The company had 102 full-time employees as of December 31, 2025.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical-stage biotechnology company developing allogeneic "off-the-shelf" gamma delta T cell therapies engineered with chimeric antigen receptors (CARs) for autoimmune diseases and cancer. Its pipeline includes product candidates targeting B cell-mediated autoimmune disorders and CD70+ solid tumors. Adicet’s proprietary platform enables scalable manufacturing from unrelated donors, offering potential advantages in safety, tissue targeting, and cost-efficiency over autologous and other cell therapies.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.